Raymond James sets USD 39.00 target for Acadia Healthcare stock

Published on 10/20/2026 at 22:03 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Acadia will report on November 4, 2026 after market close. Acadia Healthcare stock costs EUR 28.00 on October 20, 2026 at 9:59 p.m. CEST.

Analyst target and reporting date

Raymond James initiated coverage with a USD 39.00 target on September 28, 2026.
Acadia will publish third-quarter 2026 results on November 4, 2026.
Acadia Healthcare stock costs EUR 28.00 at Lang & Schwarz on October 20, 2026 at 9:59 p.m. CEST.
Acadia operated 279 facilities and approximately 12,600 beds as of June 30, 2026.

ACHC, US00404A1097, Illustration mit AI erstellt.

Raymond James initiated coverage of Acadia Healthcare with an Outperform rating and a USD 39.00 price target on September 28, 2026, according to Investing.com. At USD 31.43 on Nasdaq on October 20, 2026 at 4:00 p.m. ET, that target stood 24.09 percent above the price. The stock was trading at EUR 28.00 at Lang & Schwarz on October 20, 2026 at 9:59 p.m. CEST.

November 4 brings results

Acadia will release its third-quarter 2026 results after the market close on November 4, 2026, and hold its conference call on November 5 at 9:00 a.m. ET, according to Business Wire. The scheduled report is the next dated test for a company whose second-quarter revenue reached USD 865.8 million for the period ended June 30, 2026, according to Acadia's investor-relations page.

Stock position has a wide range

Acadia's Nasdaq price was USD 31.43 on October 20, 2026 at 4:00 p.m. ET, with a market capitalization of USD 2.9 billion and volume of 1,066,731 shares. Its 52-week range was USD 11.43 to USD 35.83 on the same date, leaving the latest price 12.28 percent below the high and 174.98 percent above the low. The company operates behavioral healthcare facilities across the United States and Puerto Rico.

What does the target imply?

The USD 39.00 Raymond James target is 24.09 percent above the October 20 Nasdaq price of USD 31.43. The report also cited professional liability dynamics as a near-term constraint and noted that the 2025 claims experience included a USD 29.00 million accrual adjustment in the second quarter.

Comparison with peers

Acadia Healthcare: up 4.14 percent on Nasdaq, market capitalization USD 2.9 billion. HCA Healthcare: up 2.40 percent on NYSE, price-to-earnings ratio 15.59, market capitalization USD 100.8 billion. Universal Health Services: up 1.85 percent on NYSE, price-to-earnings ratio 7.61, market capitalization USD 10.9 billion. These figures were dated October 20, 2026.

Two dates frame the next update

The November 4 earnings release comes first, followed by the November 5 conference call. Acadia's second-quarter 2026 adjusted EBITDA was USD 149.2 million, while full-year 2026 revenue guidance stood at USD 3.40 billion to USD 3.45 billion, according to the company's investor-relations materials.

Price remains the immediate reference

For investors, the upcoming report will place the Raymond James target beside fresh operating figures and the company's liability-cost commentary. The stock's USD 11.43 to USD 35.83 52-week range also puts the October 20 Nasdaq price below its yearly high while the euro quotation remains the relevant German trading indication. The further course of trading is shown by the continuously updated real-time quote of Acadia Healthcare stock.